Zymeworks Inc
NASDAQ:ZYME
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.11
17.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Zymeworks Inc
Zymeworks Inc
PP&E Net
Zymeworks Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zymeworks Inc
NASDAQ:ZYME
|
PP&E Net
$35.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Net
$5.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Net
$5.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
14%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Net
$6.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Net
$2.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Net
$4.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Zymeworks Inc
Glance View
Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.
See Also
What is Zymeworks Inc's PP&E Net?
PP&E Net
35.7m
USD
Based on the financial report for Sep 30, 2024, Zymeworks Inc's PP&E Net amounts to 35.7m USD.
What is Zymeworks Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
18%
Over the last year, the PP&E Net growth was -8%. The average annual PP&E Net growth rates for Zymeworks Inc have been -6% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
